News
Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...
US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback